Literature DB >> 3828484

Effect of intravenous infusion time on the pharmacokinetics and pharmacodynamics of the same total dose of furosemide.

M G Lee, T Li, W L Chiou.   

Abstract

The pharmacokinetics and pharmacodynamics of furosemide were evaluated after intravenous administration of the same total dose of furosemide in different lengths of infusion time (10 s, 30 min, 2 h, and 8 h) to 6 dogs. The fluid loss in urine was immediately replaced volume for volume with intravenous infusion of Lactated Ringer's solution. The pharmacokinetic parameters such as per cent of the dose excreted in urine, total body and renal clearances, and terminal half-life were not significantly different with four different infusion times. The volume of distribution at steady state and mean residence time based on venous data, on the other hand, appeared to increase with increasing infusion time. The mean values for Vss were 0.334, 0.478, 0.499, and 0.708 1 kg-1 for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for MRT were 17.5, 22.2, 24.8, and 38.1 min. The diuretic effects (urine output and urinary excretion of sodium) were generally found to increase with increasing infusion times; the total mean 24 h urine outputs were 1102, 1464, 2190, and 3470 ml for 10 s, 30 min, 2 h, and 8 h of infusion, respectively, and the corresponding values for sodium excretion were 170, 175, 272, and 440 mmol. Furosemide plasma concentrations and hourly urinary excretion rates of furosemide, sodium, and potassium during the apparent steady state (between 2 and 8 h) in the 8 h infusion study were fairly constant.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3828484     DOI: 10.1002/bdd.2510070603

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  9 in total

1.  Use of Emax model in diuretic studies.

Authors:  F H Noormohamed
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

2.  Pharmacokinetics and pharmacodynamics of azosemide after intravenous and oral administration to rats: absorption from various GI segments.

Authors:  S H Lee; M G Lee
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

3.  An LC-MS assay for the screening of cardiovascular medications in human samples.

Authors:  Eduardo Dias; Brian Hachey; Candace McNaughton; Hui Nian; Chang Yu; Brittany Straka; Nancy J Brown; Richard M Caprioli
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2013-08-16       Impact factor: 3.205

4.  Discrepancy between bioavailability as estimated from urinary recovery of frusemide and total diuretic effect.

Authors:  G Alván; G Paintaud; S A Eckernäs; A Grahnén
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

5.  Analysis of the natriuretic action of a loop diuretic, piretanide, in man.

Authors:  F H Noormohamed; A F Lant
Journal:  Br J Clin Pharmacol       Date:  1991-04       Impact factor: 4.335

6.  Pharmacokinetics and pharmacodynamics of bumetanide after intravenous and oral administration to rats: absorption from various GI segments.

Authors:  S H Lee; M G Lee; N D Kim
Journal:  J Pharmacokinet Biopharm       Date:  1994-02

7.  Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide.

Authors:  T Li; M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

Review 8.  Furosemide pharmacokinetics and pharmacodynamics in health and disease--an update.

Authors:  M Hammarlund-Udenaes; L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1989-02

9.  Furosemide use in Italian neonatal intensive care units: a national survey.

Authors:  Valeria Anna Manfredini; Chiara Cerini; Antonio Clavenna; Andrea Dotta; Maria Letizia Caccamo; Alex Staffler; Luca Massenzi; Rossano Massimo Rezzonico
Journal:  Ital J Pediatr       Date:  2020-06-22       Impact factor: 2.638

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.